Abbott Laboratories (ABT)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 6,896,000 | 6,709,000 | 7,835,000 | 9,161,000 | 9,882,000 | 9,594,000 | 8,937,000 | 7,675,000 | 9,799,000 | 9,302,000 | 8,658,000 | 8,054,000 | 6,838,000 | 4,480,000 | 4,763,000 | 3,377,000 | 3,860,000 | 4,091,000 | 3,137,000 | 3,022,000 |
| Short-term investments | US$ in thousands | 383,000 | 338,000 | 320,000 | 371,000 | 288,000 | 313,000 | 353,000 | 483,000 | 450,000 | 390,000 | 286,000 | 318,000 | 310,000 | 251,000 | 274,000 | 291,000 | 280,000 | 244,000 | 239,000 | 239,000 |
| Receivables | US$ in thousands | 6,565,000 | 6,499,000 | 6,172,000 | 6,020,000 | 6,218,000 | 6,408,000 | 7,199,000 | 7,179,000 | 6,487,000 | 6,405,000 | 6,113,000 | 6,096,000 | 6,414,000 | 5,649,000 | 5,140,000 | 5,292,000 | 5,425,000 | 5,450,000 | 5,548,000 | 5,345,000 |
| Total current liabilities | US$ in thousands | 13,841,000 | 13,042,000 | 14,350,000 | 14,530,000 | 15,489,000 | 13,365,000 | 12,392,000 | 12,647,000 | 13,105,000 | 12,867,000 | 12,614,000 | 12,462,000 | 11,907,000 | 10,257,000 | 10,959,000 | 10,808,000 | 10,863,000 | 10,491,000 | 9,062,000 | 9,113,000 |
| Quick ratio | 1.00 | 1.04 | 1.00 | 1.07 | 1.06 | 1.22 | 1.33 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 | 1.01 | 0.93 | 0.83 | 0.88 | 0.93 | 0.98 | 0.94 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($6,896,000K
+ $383,000K
+ $6,565,000K)
÷ $13,841,000K
= 1.00
The quick ratio of Abbott Laboratories has shown stability over the past eight quarters, ranging between 1.16 to 1.54. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets. A quick ratio above 1 indicates that the company has sufficient current assets, excluding inventory, to cover its current liabilities.
Abbott Laboratories' quick ratio has generally remained above 1, indicating that the company has a comfortable cushion to meet its short-term obligations without relying heavily on inventory. The slight fluctuations in the quick ratio over the quarters suggest that the company has maintained a relatively stable liquidity position. However, it is important to monitor any trends in the quick ratio over time to ensure the company's ability to meet its short-term obligations effectively.
Peer comparison
Dec 31, 2023